Navigation Links
Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training

Gift is among largest in the College's history

BRONX, N.Y., May 13 /PRNewswire/ -- The Albert Einstein College of Medicine of Yeshiva University today announced that it has received a major gift of $25 million -- one of the largest in the College's 53-year history -- from Ruth L. and David S. Gottesman. A photo of the Gottesmans is available.



The Gottesman gift will support several important research projects at the College of Medicine, most to be conducted in the new Michael F. Price Center for Genetic and Translational Medicine/Harold and Muriel Block Research Pavilion, which officially opens in June 2008. The Price Center/Block Research Pavilion is the largest medical research facility to be constructed in the Bronx since Einstein opened in 1955. A photo of the Price Center is available.

Funds from the gift will be allocated as follows: $15 million will be used to establish the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research; $7 million will fund The Center for Epigenomics, to be headed by Einstein researcher Dr. John Greally; and $3 million will be used to create The Ruth L. Gottesman Clinical Skills Facility in the soon-to-be renovated Van Etten Building, which Einstein has leased from Jacobi Medical Center as part of its overall expansion. In addition, the gift will support an endowed chair at the Gottesman stem cell institute and a faculty scholar in Epigenomics, as well as the recruitment of top-flight faculty that will bolster Einstein's already prominent leadership in both of these important fields.

"In discussions with the College, we determined that stem cells, epigenomics and clinical training were areas where we could help make an important contribution, both to Einstein and to the future of biomedical research," said Dr. Ruth Gottesman, who was elected chair of Einstein's Board of Overseers in 2007 and is the first woman, and the first former faculty member, to serve in that role. "We want our gift to support endeavors that will position Albert Einstein College of Medicine to excel in both research and medical education, while also attracting the best and brightest to our laboratories and to our classrooms."

"The Gottesman gift will contribute significantly to Einstein's already formidable research efforts in stem cell/regenerative medicine research and epigenomics," said Allen M. Spiegel, M.D., The Marilyn and Stanley M. Katz Dean at Einstein. "Additionally, the gift will establish an innovative facility to further enhance the training of future generations of physicians at Einstein, helping them master the clinical skills that will prepare them to be first-rate health care providers."

The specific benefits of the gift to Einstein, as well as to the patients who will be helped by the resulting research and training, are as follows:

-- Exploring the basic biology of stem cells -- discovering, for example,

how a human embryonic stem cell develops into a liver cell rather than

a brain cell -- is crucially important if stem cells are to be used to

treat a wide range of devastating human diseases. Einstein researchers

are at the forefront of this inquiry, and the Gottesman gift

establishing the Institute for Stem Cell and Regenerative Medicine

Research will help them achieve their research objectives.

Already, for example, Einstein professor Eric Bouhassira is well on the

way to directing human embryonic stem cells to form blood-forming cells

(which could save the lives of cancer patients needing transplants of

compatible blood-forming cells), and to form adult red blood cells (for

people needing blood transfusions). In the area of regenerative

medicine, the Einstein Liver Center is conducting pioneering research

to cure liver diseases and inherited disorders such as hemophilia by

implanting cells that will multiply and restore patients' damaged or

diseased organs or tissues.

-- With some 20 of its scientists studying epigenomics, Einstein ranks as

a leader in this exciting new field, which the National Institutes of

Health recently added to research programs it funds that are "expected

to have exceptionally high impact." Epigenomics is the study of the

vast network of chemical "marks" inside our cells that control the

expression of our genes, turning them on and off at certain times and

in certain tissues. These chemicals, which latch onto our genes but can

also be removed, comprise our "epigenomes" and affect our lives in

crucially important ways. Scientists now believe that many complex

diseases, such as Alzheimer's and autism, result from epigenomic

changes that cause gene regulation to go awry. Altered epigenomic marks

have also been found in every type of cancer that researchers have


Dr. Greally, an internationally recognized expert in epigenomics and

head of the new Center for Epigenomics at Einstein, has developed a

novel method for "mapping" the most important epigenomic marks: the

methyl molecules present throughout a person's genome. He has used this

method to detect the methylation patterns that characterize breast

tumors and other types of cancers. Thanks to the resources that the new

epigenomics center offers, Dr. Greally and his colleagues can now

devise therapeutic strategies aimed at erasing the epigenomic marks

that cause cancer and other diseases.

-- A portion of the Gottesman gift will greatly enhance Einstein's efforts

to impart clinical skills to its students. Teaching medical students

the basic skills of clinical examination -- how to communicate with

patients and take their histories, for example -- is crucially

important in training new doctors. Up until now, Einstein has lacked a

single, stand-alone clinical center where its medical students could

master such skills. When the new facility is built, Einstein will have

the state-of-the-art training facility that it needs.

The $25 million gift is a reflection of the Gottesmans' longstanding affiliation with the College of Medicine. In 2002, the couple endowed a professorial chair at Einstein's Children's Evaluation and Rehabilitation Center in connection with Dr. Gottesman's life-long interest in helping people with learning disabilities.

Prior to joining the Einstein Board of Overseers in 2002, Dr. Ruth Gottesman had a distinguished 33-year academic career at the medical school, beginning in 1968 when she joined Einstein's Children's Evaluation and Rehabilitation Center (CERC) to develop a program for children with dyslexia and other learning disabilities. She went on to serve as CERC's Director of Psychoeducational Services and later as Director of the Adult Literacy Program. In 1999, she became Founding Director of the Fisher Landau Center for the Treatment of Learning Disabilities, a new division of CERC that was established to provide interdisciplinary services to individuals of all ages with learning disabilities.

David Gottesman is the founder and senior managing director of the First Manhattan Company, an investment advisory firm. He was Chairman of the Board of Yeshiva University from 1990 to 1998.

About the Albert Einstein College of Medicine

The Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. It is the home to some 2,000 faculty members, 750 M.D. students, 350 Ph.D. students (including 125 in combined M.D./Ph.D. programs) and 380 postdoctoral investigators. Last year, Einstein received more than $150 million in grant funding from the National Institutes of Health (NIH). In addition, the NIH funds major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five hospital centers in the Bronx, Manhattan and Long Island -- which includes Montefiore Medical Center, Einstein's officially designated University Hospital -- the College runs the largest post-graduate medical training program in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training.

SOURCE The Albert Einstein College of Medicine of YeshivaUniversity
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
2. Transplanted cells may hold the key to curing hemophilia A, Einstein scientists report
3. World Debut for BSPs HyperQ Stress System: 57th Annual American College of Cardiology Meeting 2008
4. Boston College, MIT researchers achieve dramatic increase in thermoelectric efficiency
5. CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
6. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
7. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
10. KGI and Smith College Establish Leadership Forum for Women in Bioscience
11. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and ... they have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas ... tools for gene editing across all applications. , Under the terms of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will ... analytical testing are being attributed to new regulatory requirements for all new drug ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
Breaking Biology News(10 mins):